Sanofi's $470M Vigil Neuroscience, Inc. acquisition highlights VG-3927's potential in Alzheimer's. Click here to find out why ...

The FDA has approved Imaavy™ (nipocalimab-aahu) for the treatment of generalized myasthenia gravis in patients aged 12 years and older who are AChR or anti-muscle-specific tyrosine kinase antibody ...

Given the probability of trial success and current valuation, we rate the ATYR stock 'Hold' as risk and reward appear ...

Despite the well-recognized involvement of immunoglobulin (Ig) A in mucosal immunity, the function of its receptor ... production of oxygen radicals in human polymorphonuclear cells, which ...

Parallel Bio, a biotech company pioneering human-first drug discovery, today announced it has raised $21 million Series A ...

DNA's double helix has long stood as the symbol of life’s code. But buried within the genome lies a deeper level of ...

A compound derived from rosemary, known as carnosic acid, has been transformed into a potent brain-boosting drug that combats Alzheimer’s by reducing inflammation and stress in the brain — all while ...

The simplicity of Merck's monoclonal antibody for RSV in infants could be a plus in its competition with AstraZeneca's existing treatment.

SLC35B1 transports ATP into the ER, and its structure offers potential for targeted therapies in diseases linked to ER stress ...

National Institutes of Health Director Jay Bhattacharya claimed the dean of Stanford Medical School asked him to stop ...

Eli Lilly is beefing up muscle health R&D, partnering with Juvena Therapeutics in a deal that includes an upfront fee and ...